Cargando…

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens

BACKGROUND: KRAS mutation testing is required to select patients with metastatic colorectal cancer (CRC) to receive anti-epidermal growth factor receptor antibodies, but the optimal KRAS mutation test method is uncertain. METHODS: We conducted a two-site comparison of two commercial KRAS mutation ki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez de Castro, D, Angulo, B, Gomez, B, Mair, D, Martinez, R, Suarez-Gauthier, A, Shieh, F, Velez, M, Brophy, V H, Lawrence, H J, Lopez-Rios, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394984/ https://www.ncbi.nlm.nih.gov/pubmed/22713664 http://dx.doi.org/10.1038/bjc.2012.259

Ejemplares similares

Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform
por: Abramovitz, M, et al.
Publicado: (2011)

Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material
por: Gravendeel, L A M, et al.
Publicado: (2012)

Exon-array profiling unlocks clinically and biologically relevant gene signatures from formalin-fixed paraffin-embedded tumour samples
por: Hall, J S, et al.
Publicado: (2011)

Reply to comment by Normanno et al on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: de Castro, D G, et al.
Publicado: (2012)

Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours
por: Linton, K M, et al.
Publicado: (2008)

Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer
por: Lopez-Rios, Fernando, et al.
Publicado: (2013)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: Normanno, N, et al.
Publicado: (2012)

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
por: Deschoolmeester, V, et al.
Publicado: (2010)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma
por: Lee, Sung, et al.
Publicado: (2011)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study
por: Horsch, M, et al.
Publicado: (2009)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
por: Hamidi, H, et al.
Publicado: (2014)

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
por: van Grieken, N C T, et al.
Publicado: (2013)

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma
por: Sunaga, N, et al.
Publicado: (2014)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Construction of tissue microarrays from prostate needle biopsy specimens
por: Jhavar, S, et al.
Publicado: (2005)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers
por: Savic, S, et al.
Publicado: (2008)

Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer
por: Nonomura, N, et al.
Publicado: (2007)

Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival
por: Hanly, A M, et al.
Publicado: (2006)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene
por: Mariani, Sara, et al.
Publicado: (2017)

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
por: Saridaki, Z, et al.
Publicado: (2015)

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
por: Renaud, Stéphane, et al.
Publicado: (2015)

Rapid nodal staging of head and neck cancer surgical specimens with flow cytometric analysis
por: Häyry, Valtteri, et al.
Publicado: (2018)

Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer
por: Oshita, F, et al.
Publicado: (2006)

Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery
por: Renaud, Stéphane, et al.
Publicado: (2016)

PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS
por: Stichel, Damian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7iqu283n3nek8v1k95uje3rs8k